Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

1. Orlowski, R.Z.
2. Nagler, A.
3. Sonneveld, P.
4. Bladé, J.
5. Hajek, R.
6. Spencer, A.
7. Robak, T.
8. Dmoszynska, A.
9. Horvath, N.
10. Spicka, I.
11. Sutherland, H.J.
12. Suvorov, A.N.
13. Xiu, L.
14. Cakana, A.
15. Parekh, T.
16. San-Miguel, J.F.